Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6646 to 6660 of 7691 results

  1. Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]

    Discontinued [GID-TA10213]

  2. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued [GID-TA10377]

  3. Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]

    Discontinued [GID-TAG431]

  4. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued [GID-TA10151]

  5. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued [GID-TA10244]

  6. Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]

    Discontinued [GID-TA10443]

  7. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued [GID-TA10033]

  8. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

  9. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued [GID-TAG398]

  10. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued [GID-TA10099]

  11. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued [GID-TA10306]

  12. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development [GID-TA11022] Expected publication date: TBC

  13. The MAGEC system for spinal lengthening in children with scoliosis (MT169)

    Discontinued [GID-MT544]

  14. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued [GID-TAG433]

  15. Diabetic foot ulcers - new treatments [ID381]

    Discontinued [GID-TAG371]